Clinical trial NCT05282693: Ergogenic Properties of Magnesium Supplementation
Official title: Ergogenic Properties of Magnesium Supplementation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise Performance
Gut -Microbiota
Mitochondrial Function
Lead sponsor: Colorado State University
Sponsor class: OTHER
First posted: 2022-03-16
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Participants will be randomized to either placebo for 9-days of the intervention separated by a 3-week washout period.
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the proposed project is to determine if short-term dietary supplementation of magnesium will improve performance during a series of lab-based exercise tests, will favorably modify the gut-microbiota, and will augment skeletal muscle mitochondrial function.

Detailed description: Magnesium is the fourth most abundant mineral in the human body. It is critical to day-to-day physiological function including the regulation of metabolism, cardiovascular function, immune function, and the operation of the nervous system. In light of its important role in physiology, dietary supplementation of magnesium has been purported to improve athletic performance, although the precise mechanism is unclear. The foci of the proposed study is the ergogenic effects of magnesium, its potential influence on gut health, and its potential ability to improve skeletal muscle function. The investigators will be studying an athletic/competitive population of endurance-trained adults. This group is likely to be the most interested in the use of magnesium to enhance athletic performance. Also, by only recruiting habitual exercisers, the variability between participants is likely to be reduced compared with if the investigators had also recruited people who are usually sedentary.

Eligibility criteria: Inclusion Criteria:

* Competitive cyclists
* Adult males and females (18 - 40 years, inclusive) who have exercised a minimum of 5 days per week, for a minimum of 30-minutes/session, during the previous 2 years.
* Maximal oxygen uptake (VO2max) satisfying the minimum criteria for "Good" (sex- and age-adjusted) as defined by the American College of Sports Medicine.

Exclusion Criteria:

* Identification of a contra-indication to exercise during a 12-lead exercise stress test
* Use of a magnesium supplement within the previous 4 weeks
* Pregnancy or breast-feeding
* Unable to perform vigorous exercise
* History (previous diagnosis) of kidney disease
* Use of laxatives, Zinc, diuretics, proton pump inhibitors, over the counter agents such as certain heartburn and GI/gut treatments (laxatives) which contain magnesium, Zinc or other high dose cations which reduce absorption of Magnesium

Primary outcomes:
measure: Comparison of completion of time trial to placebo
timeFrame: After 9 days of intervention
measure: Comparison of power output to placebo
timeFrame: After 9 days of intervention
measure: Comparison of indirect Calorimetry (VO2max) to placebo
timeFrame: After 8 days of intervention
measure: Comparison of lactate threshold to placebo
timeFrame: After 8 days of intervention
measure: Comparison of Mitochondrial Function to placebo
timeFrame: After 8 days of intervention
measure: Comparison of Shannon and Faith's microbiota diversity scores in feces to placebo
timeFrame: After 9 days of intervention,
measure: Calculation and ordination of B-diversity scores for all fecal samples to assess clustering
timeFrame: After 9 days of intervention
measure: Determination of differentially abundant microbiota in feces of collected during treatment compared to placebo
timeFrame: After 9 days of intervention
measure: Comparison of abundant microbiota to markers in feces to placebo
timeFrame: After 9 days of intervention
measure: Comparison Human Granulocyte Macrophage Colony-Stimulating Factor to placebo
timeFrame: After 9 days of intervention
measure: Comparison interferon gamma to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 1 beta to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 2 to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 4 to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 5 to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 6 to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 7 to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 8 to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 10 to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 12 (p70) to placebo
timeFrame: After 9 days of intervention
measure: Comparison interleukin 13 to placebo
timeFrame: After 9 days of intervention
measure: Comparison Tumor Necrosis Factor alpha to placebo
timeFrame: After 9 days of intervention
measure: Comparison High-sensitivity C-reactive protein to placebo
timeFrame: After 9 days of intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Collins
country: United States
facility: Colorado State University, Dept. of Health and Exercise Science
state: Colorado
Study officials:
References: